105 related articles for article (PubMed ID: 15687599)
1. Suppressing HER2/neu-mediated cell transformation by transcriptional repressors.
Hung MC; Wang SC
Breast Dis; 2000; 11():133-44. PubMed ID: 15687599
[TBL] [Abstract][Full Text] [Related]
2. Targeting HER2: recent developments and future directions for breast cancer patients.
Wang SC; Zhang L; Hortobagyi GN; Hung MC
Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional targeting of the HER-2/neu oncogene.
Wang SC; Hung MC
Drugs Today (Barc); 2000 Dec; 36(12):835-43. PubMed ID: 12845342
[TBL] [Abstract][Full Text] [Related]
4. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
5. HER2 overexpression and cancer targeting.
Wang SC; Hung MC
Semin Oncol; 2001 Oct; 28(5 Suppl 16):115-24. PubMed ID: 11706403
[TBL] [Abstract][Full Text] [Related]
6. Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9).
Menendez JA; Lupu R
Curr Pharm Biotechnol; 2006 Dec; 7(6):495-502. PubMed ID: 17168666
[TBL] [Abstract][Full Text] [Related]
7. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer.
Benz CC; O'Hagan RC; Richter B; Scott GK; Chang CH; Xiong X; Chew K; Ljung BM; Edgerton S; Thor A; Hassell JA
Oncogene; 1997 Sep; 15(13):1513-25. PubMed ID: 9380403
[TBL] [Abstract][Full Text] [Related]
8. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
Menendez JA; Papadimitropoulou A; Vellon L; Lupu R
Eur J Cancer; 2006 Oct; 42(15):2425-32. PubMed ID: 16406575
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal domain of SV40 large T antigen represses the HER2/neu-mediated transformation and metastatic potential in breast cancers.
Chuang TC; Yu YH; Lin YS; Wang SS; Kao MC
FEBS Lett; 2002 Jan; 511(1-3):46-50. PubMed ID: 11821047
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical study of HER-2/neu-targeting cancer gene therapy.
Xing X; Yujiao Chang J ; Hung M
Adv Drug Deliv Rev; 1998 Mar; 30(1-3):219-227. PubMed ID: 10837613
[TBL] [Abstract][Full Text] [Related]
11. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase.
O'Hagan RC; Hassell JA
Oncogene; 1998 Jan; 16(3):301-10. PubMed ID: 9467955
[TBL] [Abstract][Full Text] [Related]
12. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
[TBL] [Abstract][Full Text] [Related]
13. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
Lu H; Qin H; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
[TBL] [Abstract][Full Text] [Related]
14. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.
Hortobagyi GN; Ueno NT; Xia W; Zhang S; Wolf JK; Putnam JB; Weiden PL; Willey JS; Carey M; Branham DL; Payne JY; Tucker SD; Bartholomeusz C; Kilbourn RG; De Jager RL; Sneige N; Katz RL; Anklesaria P; Ibrahim NK; Murray JL; Theriault RL; Valero V; Gershenson DM; Bevers MW; Huang L; Lopez-Berestein G; Hung MC
J Clin Oncol; 2001 Jul; 19(14):3422-33. PubMed ID: 11454891
[TBL] [Abstract][Full Text] [Related]
15. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
Xing X; Matin A; Yu D; Xia W; Sorgi F; Huang L; Hung MC
Cancer Gene Ther; 1996; 3(3):168-74. PubMed ID: 8725881
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
Zhang Y; Yu D; Xia W; Hung MC
Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
[TBL] [Abstract][Full Text] [Related]
17. PEA3 cooperates with c-Jun in regulation of HER2/neu transcription.
Matsui K; Sugimori K; Motomura H; Ejiri N; Tsukada K; Kitajima I
Oncol Rep; 2006 Jul; 16(1):153-8. PubMed ID: 16786139
[TBL] [Abstract][Full Text] [Related]
18. SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu.
Wen CC; Cheng SA; Hsuen SP; Huang YL; Kuo ZK; Lee HF; Kuo CH; Du JL; Wang WB
Cancer Res; 2006 Jun; 66(11):5847-57. PubMed ID: 16740724
[TBL] [Abstract][Full Text] [Related]
19. Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu.
Chen H; Yu D; Chinnadurai G; Karunagaran D; Hung MC
Oncogene; 1997 Apr; 14(16):1965-71. PubMed ID: 9150363
[TBL] [Abstract][Full Text] [Related]
20. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.
Yu D; Shi D; Scanlon M; Hung MC
Cancer Res; 1993 Dec; 53(23):5784-90. PubMed ID: 7902209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
